Trial Now Recruiting: A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC (NCT06010329)
WHY IT MATTERS
If you have metastatic or locally advanced non-small cell lung cancer with uncommon EGFR mutations, this trial offers access to a potentially new treatment option that may not yet be available outside of clinical research.
Researchers are testing a new cancer drug called sutetinib maleate in people with advanced lung cancer that has specific uncommon genetic mutations. This is a Phase 2 trial, meaning the drug has already been tested in a small group and now researchers want to see if it works better and remains safe in a larger group of 66 patients. The study is currently accepting new participants.
NCT ID: NCT06010329 Status: RECRUITING Conditions: Non-small Cell Lung Cancer Phase: PHASE2 Enrollment: 66 Sponsor: Teligene US Summary: The main objective of the study will be to evaluate the efficacy of sutetinib maleate capsules in participants with locally advanced or metastatic non-small cell lung cancer NSCLC (uncommon EGFR mutations only).
YOU CAN ACT ON THIS
If you have the qualifying lung cancer type with uncommon EGFR mutations, contact the trial sponsor (Teligene US) or visit clinicaltrials.gov with NCT ID NCT06010329 to learn about enrollment locations and eligibility requirements.